DiaMedica Updates on DM199 Opportunity in South East Asia

DiaMedica Inc. (TSXV:DMA, OTCQB:DMCAF) provided investors with a corporate update.
According to the company’s press release:

The Company has commenced discussions for potential collaboration with Chinese pharmaceutical firms for the development and commercialization of DM199 (recombinant human kallikrein-1). DM199 is potentially a replacement of the approved urine-derived kallikrein-1 protein trade named Kailikang^® in Southeast Asia for the treatment of acute ischemic stroke. DM199 is a recombinant (synthetic) form of the urine-derived kallikrein-1 product containing the same number and sequence of amino acids. Industry sources have indicated that Kailikang^® is a widely used commercially viable product in the Republic of China.

Click here to view the full press release.